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Background. The CD4 T cell count recovery in human immunodeficiency virus type 1 (HIV-1)–infected
individuals receiving potent antiretroviral therapy (ART) shows high variability. We studied the determinants and
the clinical relevance of incomplete CD4 T cell restoration.
Methods. Longitudinal CD4 T cell count was analyzed in 293 participants of the Swiss HIV Cohort Study
who had had a plasma HIV-1 RNA load !1000 copies/mL for 5 years. CD4 T cell recovery was stratified by
CD4 T cell count 5 years after initiation of ART (500 cells/mL was defined as a complete response, and !500
cells/mL was defined as an incomplete response). Determinants of incomplete responses and clinical events were
evaluated using logistic regression and survival analyses.
Results. The median CD4 T cell count increased from 180 cells/mL at baseline to 576 cells/mL 5 years after
ART initiation. A total of 35.8% of patients were incomplete responders, of whom 47.6% reached a CD4 T cell
plateau !500 cells/mL. Centers for Disease Control and Prevention HIV-1 disease category B and/or C events
occurred in 21% of incomplete responders and in 14.4% of complete responders ( ). Older age (adjustedP 1 .05
odds ratio [aOR], 1.71 per 10-year increase; 95% confidence interval [CI], 1.21–2.43), lower baseline CD4 T cell
count (aOR, 0.37 per 100-cell increase; 95% CI, 0.28–0.49), and longer duration of HIV infection (aOR, 2.39 per
10-year increase; 95% CI, 1.19–4.81) were significantly associated with a CD4 T cell count !500 cells/mL at 5 years.
The median increases in CD4 T cell count after 3–6 months of ART were smaller in incomplete responders
( ) and predicted, in conjunction with baseline CD4 T cell count and age, incomplete response with 80%P ! .001
sensitivity and 72% specificity.
Conclusion. Individuals with incomplete CD4 T cell recovery to !500 cells/mL had more advanced HIV-1
infection at baseline. CD4 T cell changes during the first 3–6 months of ART already reflect the capacity of the
immune system to replenish depleted CD4 T lymphocytes.
The key feature of untreated HIV-1 infection is the
progressive depletion of CD4 T lymphocytes. The major
achievement of potent antiretroviral therapy (ART)
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consists of a durable suppression of viral replication, a
steep increase in the CD4 T cell count, and a partial
reversal of HIV-1–associated immunological alterations
[1–7]. A complete and durable restoration of the CD4
T cell count and, particularly, of critical T cell subsets,
such as naive cells, can be best achieved by very early
initiation of ART, preferably during primary HIV-1 in
Presented in part: 11th Conference on Retroviruses and Opportunistic Infections,
San Francisco, 2004 (abstract 557).
a Members of the study group are listed at the end of the text.
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Table 1. Baseline characteristics for 293 HIV-1–infected, treatment-naive patients in the Swiss HIV Cohort Study.
Characteristic
All patients
(n p 293)
All patients, by CD4
T cell response
Patients with an incomplete response,
by CD4 T cell plateau
Complete
(n p 188)
Incomplete
(n p 105) P
Present
(n p 50)
Absent
(n p 55) P
Sex
Male 216 (73.7) 136 (72.3) 80 (76.2) .473 37 (74.0) 43 (78.2) .615
Female 77 (26.3) 52 (27.7) 25 (23.8) 13 (26.0) 12 (21.8)
Age, mean years  SD 37.8  9.3 36.5  8.8 40.0  9.7 .001 39.9  9.7 40.1  9.8 .936
Ethnicity
White 257 (87.7) 159 (84.6) 98 (93.3) .171 44 (88.0) 54 (98.2) .163
Black 16 (5.5) 13 (6.9) 3 (2.9) 2 (4.0) 1 (1.8)
Hispanic 5 (1.7) 5 (2.7) 0 (0.0) 0 (0.0) 0 (0.0)
Asian 6 (2.0) 5 (2.7) 1 (1.0) 1 (2.0) 0 (0.0)
Not available 9 (3.1) 6 (3.2) 3 (2.9) 3 (6.0) 0 (0.0)
HIV transmission category
Homosexual 127 (43.3) 81 (43.1) 46 (43.8) .215 20 (40.0) 26 (47.3) .842
Heterosexual 95 (32.4) 68 (36.2) 27 (25.7) 13 (26.0) 14 (25.5)
Injection drug user 59 (20.1) 33 (17.6) 26 (24.8) 14 (28.0) 12 (21.8)
Other/unknown 12 (4.2) 6 (3.2) 6 (5.8) 3 (6.0) 3 (5.5)
Duration of HIV-1 infection,
mean years  SD 4.4  4.4 3.8  4.1 5.4  4.7 .026 5.7  4.6 5.1  4.9 .430
CDC HIV-1 disease category
A 147 (51.0) 116 (63.4) 31 (29.5) !.001 18 (36) 13 (23.6) .375
B 96 (33.3) 46 (25.1) 50 (47.6) 22 (44) 28 (50.9)
C 45 (15.6) 21 (11.5) 24 (22.9) 10 (20) 14 (25.5)
Year of antiretroviral therapy
initiation
1996 58 (19.8) 32 (17.0) 26 (24.8) .215 10 (20.0) 16 (29.1) .388
1997 185 (63.1) 125 (66.5) 60 (57.1) 32 (64.0) 28 (50.9)
1998 50 (17.1) 31 (16.5) 19 (18.1) 8 (16.0) 11 (20.0)
Baseline HIV-1 RNA load,
log10 copies/mL 4.9 (4.3–5.4) 4.8 (4.2–5.3) 5.1 (4.6–5.6) .001 5.1 (4.6–5.5) 5.1 (4.7–5.6) .900
Baseline T cell count, cells/mL 1188 (810–1697) 1304 (970–1832) 960 (540–1348) !.001 990 (545–1516) 931 (532–1194) .357
Baseline CD4 T cell count, cells/mL 180 (60–311) 255 (127–355) 72 (29–153) !.001 93 (48–197) 58 (25–98) .021
Baseline CD8 T cell count, cells/mL 687 (420–987) 745 (450–1074) 595 (300–871) .004 626 (326–978) 556 (298–832) .590
Anti–hepatitis B virus surface
antigen positivea 14 (5.8) 7 (4.4) 7 (8.6) .185 2 (5.0) 5 (12.2) .249
Anti–hepatitis C virus positive 85 (29.0) 44 (23.5) 41 (39.0) .005 23 (46.0) 18 (32.7) .164
NOTE Data are medians and interquartile ranges or proportions, unless otherwise indicated. See Methods for definitions of complete and incomplete
CD4 T cell response and CD4 T cell plateau. CDC, Centers for Disease Control and Prevention.
a Data are for 240 patients.
fection [8, 9]. In chronic HIV-1 infection, the recovery of the
CD4 T cell count is hindered by residual viral replication, im-
paired thymic function, advanced age, enhanced T cell acti-
vation and apoptosis, and, possibly, viral coinfection [7, 10–
13]. As a consequence, a substantial proportion of treated
individuals show incomplete or even poor CD4 T cell recovery
[6, 14]. In some studies, CD4 T cell counts seemed to reach a
plateau after the first 2–3 years of ART [7, 15, 16], whereas
other studies found that, for selected groups of patients with
a well-suppressed HIV-1 RNA load, there were continuous,
albeit small increases in CD4 T cell counts even after 3–4 years
of ART [11, 17]. Thus, long-term CD4 T cell recovery, including
its modulating factors, needs further evaluation.
In this study, we addressed 3 important issues. First, we
analyzed CD4 T cell and CD8 T cell counts during a minimum
observation period of 5 years in a large, highly selected cohort
of 293 HIV-1–infected individuals with continuously sup-
pressed plasma HIV-1 RNA load, to characterize individual
patterns of CD4 T cell recovery. Second, we evaluated the clin-
ical relevance of incomplete CD4 T cell recovery to !500 cells/
mL. Third, we studied potential determinants of CD4 T cell
recovery, with the goal of predicting CD4 T cell responses dur-
ing the first months of ART. We hypothesized that advanced
immunodeficiency would limit CD4 T cell recovery and that
CD4 T cell kinetics before initiation of ART might predict of
the magnitude of CD4 T cell recovery during ART [7].
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Table 2. Initial antiretroviral therapy (ART) regimen for 293 HIV-1–infected,
treatment-naive patients in the Swiss HIV Cohort Study.
ART regimen
All
patients
(n p 293)
All patients, by CD4
T cell response
Complete
(n p 188)
Incomplete
(n p 105) P
Protease inhibitor(s)
Indinavir and 2 NAs 130 (44.4) 81 (43.1) 49 (46.7) .554
Nelfinavir and 2 NAs 82 (28.0) 52 (27.7) 30 (28.6) .868
Ritonavir and 2 NAs 45 (15.4) 29 (15.4) 16 (15.2) .966
Saquinavir-ritonavir and 2 NAs 30 (10.2) 23 (12.2) 7 (6.7) .132
Other protease or NNRTI 6 (2.0) 3 (1.6) 3 (2.8)
NRTI combination
Azidothymidine-lamivudine 160 (54.6) 96 (51.1) 64 (61) .103
Stavudine-lamivudine 74 (25.3) 53 (28.2) 21 (20) .122
Stavudine-didanosine 26 (8.9) 14 (7.4) 12 (11.4) .250
Other NAs 33 (11.2) 25 (13.3) 8 (7.6)
NOTE. Data are no. (%) of patients. See Methods for definitions of complete and incomplete
CD4 T cell response. NA, nucleoside analogue; NNRTI, nonnucleoside analogue reverse-tran-
scriptase inhibitor; NRTI, nucleoside analogue reverse-transcriptase inhibitor.
METHODS
Study design. We studied longitudinal CD4 T cell counts,
CD8 T cell counts, and plasma HIV-1 RNA levels in 293 treat-
ment-naive, HIV-1–infected persons in the Swiss HIV Cohort
Study up to 4 years before and during a minimum follow-up
period of 5 years after initiation of ART. Laboratory data were
collected every 3–6 months. ART was defined as a combination
of at least 3 antiretroviral drugs, including either 2 nucleoside
analogue reverse-transcriptase inhibitors (NRTIs) in combi-
nation with a protease inhibitor or a non-NRTI (NNRTI), 2
protease inhibitors in combination with at least 1 NRTI, a
combination of a protease inhibitor and an NNRTI with at
least 1 NRTI, or a combination of 3 NRTIs.
Because the objective was to study the maximum regenerative
capacity of the immune system, the analysis was restricted to
patients who achieved and maintained plasma HIV-1 RNA
loads of !1000 copies/mL during the entire 5-year observation
period. The threshold was a trade-off between a reasonably
good virologic response and a sufficiently large sample size that
allowed a meaningful statistical analysis. A total of 3234 in-
dividuals were excluded; 802 had missing baseline values, 2200
had 1 viral load measurement 1000 copies/mL after 6
months, and 32 commenced ART with a CD4 T cell count
500 cells/mL.
Data analysis. The primary end point was the recovery of
the CD4 T cell count within 5 years after ART initiation. Com-
plete and incomplete CD4 T cell responses were defined by
CD4 T cell counts 500 or !500 cells/mL, respectively, at 5
years. The threshold of 500 cells/mL was chosen because, for
many laboratories, it represents the lower boundary of the nor-
mal range. Determinants of CD4 T cell responses were eval-
uated by means of a multivariate logistic regression model that
evaluated demographic characteristics as well as HIV-specific
variables. Calculation of the duration of HIV-1 infection was
based on the date of the first documented positive HIV-1 se-
rologic test result in a reference laboratory (for 76.2% of pa-
tients) or the date on which evidence of a previous positive
HIV-1 serologic test result was recorded, as revealed by an
analysis of patient medical histories (for 23.8% of patients). A
receiver operating characteristics curve analysis was used to
evaluate the accuracy of different models to predict incomplete
CD4 T cell responses, using data for 2 different cohorts [6, 7].
The kinetics of the replenishment of the CD4 T cell pool
was analyzed by fitting a mathematical model to individual
patient data using a nonlinear regression routine (MatLab;
MathWorks). CD4 T cell count at time t is given by
l1(1e
m
1*
t
2e
m
2*
t. The model assumes that the regenera-) + l
tion of CD4 T lymphocytes occurs at a constant rate, whereas
cells are eliminated in accordance with first-order kinetics. The
second term accounts for the rapid redistribution of CD4 T
cells from lymphoid tissue into peripheral blood at the time
virus replication is suppressed [19]. The model was developed
and tested in a different cohort of patients before it was applied
in this study [6, 18].
New or relapsing HIV-1–related clinical events (Centers for
Disease Control and Prevention [CDC] HIV disease categories
B and C) that occurred after initiation of ART for individuals
with complete and individuals with incomplete CD4 T cell
Figure 1. Time course of CD4 T cell count before (A) and after (B) initiation of antiretroviral therapy (ART). C, Median changes in CD4 T cell counts
during consecutive time intervals after ART initiation. Data are medians and interquartile ranges. See Methods for definitions of complete and incomplete
CD4 T cell response.
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Figure 2. A, Time course of CD8 T cell count after antiretroviral therapy (ART) initiation. B, Time course of plasma HIV-1 RNA load after ART
initiation. Data are medians and interquartile ranges. See Methods for definitions of complete and incomplete CD4 T cell response.
responses were compared using a Cox proportional hazards
model. To account for possible immune reconstitution illness,
early and late clinical events after initiation of ART (12 and
112 months, respectively) were analyzed separately.
Continuous data for the groups with complete and incom-
plete CD4 T cell recovery and the groups that did and did not
reach a CD4 T cell plateau were compared by means of a Mann-
Whitney U test, whereas categorical data were compared by
means of a x2 test. The relationship between continuous var-
iables was analyzed with Spearman’s rank-order correlation
coefficient.
Continuous data are presented as medians (interquartile
range), except for age and duration of HIV-1 infection, which
are shown as . All statistical analyses were per-means SD
formed using SPSS, version 11.0 (SPSS). A 2-sided P value !.05
was considered to be statistically significant.
RESULTS
Patient characteristics. The age of the patients was 37.8
years; 73.7% were male, and 87.7% were white. The du-9.3
ration of HIV-1 infection was years. HIV-1 disease4.4 4.4
in 51.0% was classified as CDC category A. Additional baseline
characteristics are shown in tables 1 and 2.
Time course of CD4 T lymphocyte count before initiation
of ART. The CD4 T lymphocyte count decreased from 410
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Table 3. Multivariate logistic regression analysis revealing determinants of an incomplete
CD4 T cell response for 293 HIV-1–infected, treatment-naive patients in the Swiss HIV Cohort
Study.
Parameter
Unadjusted OR
(95% CI) P
Adjusteda OR
(95% CI) P
Female sex 0.82 (0.47–1.42) .473 1.07 (0.51–2.25) .853
Ageb 1.51 (1.16–1.96) .002 1.71 (1.21–2.43) .003
Duration of HIV-1 infectionc 2.30 (1.28–4.15) .005 2.39 (1.19–4.81) .015
HIV transmission group
Homosexual 1.0 1.0
Heterosexual 0.70 (0.39–1.24) .222 0.85 (0.40–1.80) .670
Injection drug user 1.39 (0.74–2.60) .307 0.74 (0.30–1.81) .508
Anti–hepatitis C virus positive 2.08 (1.24–3.49) .005 1.36 (0.66–2.79) .401
Hepatitis B virus surface antigen positive 2.05 (0.70–6.07) .193 2.75 (0.61–12.41) .189
CDC HIV-1 disease category
A 1.00 1.00
B 4.07 (2.32–7.14) !.001 1.09 (0.50–2.37) .838
C 4.28 (2.11–8.67) !.001 0.89 (0.35–2.28) .805
Baseline HIV-1 RNA loadd 1.49 (1.11–1.99) .008 1.01 (0.73–1.40) .964
Baseline CD4 T cell counte 0.37 (0.28–0.47) !.001 0.37 (0.28–0.49) !.001
Baseline CD8 T cell counte 0.93 (0.88–0.98) .005 1.03 (0.96–1.10) .425
NOTE. See Methods for definition of incomplete CD4 T cell response. CDC, Centers for Disease Control and
Prevention.
a Adjusted for baseline CD4 T cell count, duration of HIV-1 infection, and age.
b Per 10-year increase in age.
c Per 1-year increase in duration.
d Per 1 log increase in the plasma HIV-1 RNA load.
e Per 100 cells/mL increase.
cells/mL (256–538 cells/mL) 4 years before the initiation of ART
(for 37 patients) to 180 cells/mL (60–311 cells/mL) at baseline,
when ART was initiated (for 293 patients). During the same
period, the percentage of CD4 T lymphocytes decreased from
23% (19%–30%) 4 years before initiation of ART to 13% (6%–
22%) at baseline (data not shown). The annual changes in the
CD4 T lymphocyte count before the onset of ART were 43
cells/mL (85 to +3 cells/mL) during the fourth year,35 cells/
mL (85 to 2 cells/mL) during the third year, 55 cells/mL
(106 to 10 cells/mL) during the second year, and68 cells/
mL (30 to130 cells/mL) during the previous year. The annual
changes in the CD4 T cell percentage during these intervals
were 2% (4.5% to 0%), 2% (4.0% to 0%), 2%
(3.0% to 0%), and 3% (6.0% to 1.0%), respectively.
Long-term recovery of CD4 T lymphocytes during ART.
Absolute CD4 T lymphocyte counts increased from 180 cells/
mL at time of ART initiation (60–311 cells/mL) to 576 cells/mL
(401–743 cells/mL) 5 years later, whereas the percentage of CD4
T cells increased from 13% (6%–22%) to 30% (23%–37%).
CD4 T cell counts increased to 1200 cells/mL in 98.0% of pa-
tients, to 1350 cells/mL in 82.6%, and to 1500 cells/mL in 59.0%.
The analysis of CD4 T cell kinetics during the first 3 months
after initiation of ART initiation revealed an increase in CD4
T cell count of 80 cells/mL (27–143 cells/mL). Increases during
subsequent intervals gradually became smaller (172 cells/mL
[103–243 cells/mL] during the first year of ART, 80 cells/mL
[24–143 cells/mL] during the second year, 63 cells/mL [4 to
136 cells/mL] during the third year, 28 cells/mL [36 to 97 cells/
mL] during the fourth year, and 27 cells/mL [45 to 102 cells/
mL] during the fifth year). Annual increases in the percentage
of CD4 T cells during years 1–5 after ART initiation were 8%
(5%–12%), 3% (1%–5%), 2% (0%–3%), 1% (0%–3%), and
1% (0%–3%). The decrease in the CD4 T cell count during
the final 2 years before initiation of ART was significantly as-
sociated with increases in the CD4 T cell count during the first
3 and 6 months after ART initiation ( [ ] andrp 0.41 Pp .003
[ ], respectively) but not with changes 16rp 0.399 Pp .004
months after ART initiation.
The CD8 T cell count increased from 687 cells/mL (420–987
cells/mL) to 817 cells/mL (595–1096 cells/mL), whereas the per-
centage of CD8 T cells decreased from 60% (50%–69%) to
44% (37%–52%).
Characteristics of patients with incomplete CD4 T cell
recovery. Patients with incomplete and patients with complete
CD4 T cell responses (hereafter, “incomplete responders” and
“complete responders,” respectively) showed similar changes in
CD4 T cell counts during the 2 years before the initiation of
ART (116 vs. 105 cells/mL; ; figure 1A), but in-Pp .759
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Figure 3. Distinct patterns of CD4 T cell recovery in 4 patients for whom the CD4 T cell count reached a plateau !500 cells/mL (A and B) or
showed a slow, but steady increase (C and D).
complete responders commenced ART at lower CD4 T cell
counts than did complete responders (72 vs 255 cells/mL; P !
). During the first 5 years after ART initiation, annual in-.001
creases in the CD4 T cell count were significantly smaller for
incomplete responders, compared with complete responders
(109 vs. 203 cells/mL during the first year after ART initiation
[ ], 59 vs. 98 cells/mL during the second year [ ],P ! .001 P ! .001
54 vs. 83 cells/mL during the third year [ ], 19 vs. 54Pp .020
cells/mL during the fourth year [ ], and 22 vs. 30 cells/Pp .032
mL during the fifth year [ ]; figure 1B and 1C). EvenPp .463
changes in the CD4 T cell count during the first 3 months after
therapy differed significantly between incomplete and complete
responders (52 vs. 103 cells/mL; ). This finding suggestsP ! .001
that incomplete and complete responders may be distinguished
on the basis of early differences in CD4 T cell kinetics.
Similarly, the increase in the CD4 T cell percentage during
the first year of ART was significantly smaller in incomplete
responders than in complete responders (7% vs. 8%; Pp
). However, changes in CD4 T cell percentages during sub-.016
sequent intervals were comparable (3% for nonresponders and
3% for responders during the second year, 2% and 2% during
the third year, 1% and 1% during the fourth year, and 0% and
0% during the fifth year).
At all time points, absolute CD8 T cell counts and CD8 T
lymphocyte percentages were significantly lower for incomplete
responders than for complete responders (734 vs. 869 cells/mL
[ ; figure 2A] and 50.0% vs. 41% [ ], respec-Pp .003 P ! .001
tively, after 60 months of therapy). These findings most likely
reflect the more advanced stage of HIV-1 infection in incom-
plete responders and are supported by the highly significant
relationship between the baseline CD4 and CD8 T cell counts
( ; )rp 0.499 P ! .001
Incomplete responders had higher plasma HIV-1 RNA loads
at baseline, compared with complete responders (5.1 vs. 4.8
log10 copies/mL; ), as well a larger decrease in thePp .001
plasma HIV-1 RNA load during the first 3 months of ART (2.9
vs. 2.7 log10 copies/mL [ ]) and during the first 6 monthsPp .02
of ART (3.8 vs. 3.4 log10 copies/mL [ ]) (figure 2B). TherePp .01
was also a trend toward a higher area under the plasma HIV-
1 RNA curve for incomplete responders, compared with com-
plete responders ( ).Pp .055
Demographic and HIV-1–related variables at baseline dif-
fered significantly between complete and incomplete respond-
ers. Incomplete responders were older (40.0 vs. 36.5 years;
), had HIV-1 infection for a longer period (5.4 vs. 3.8Pp .001
years; ), and had a higher prevalence of CDC categoryPp .026
C disease (22.9% vs. 11.5%; ). In a multivariate logisticP ! .001
regression model, baseline CD4 T cell count (adjusted OR, 0.37
per 100-cell increase; 95% CI, 0.28–0.49; ), age (ad-P ! .001
justed OR, 1.71 per 10-year increase; 95% CI, 1.21–2.43;
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Figure 4. Proportions of complete CD4 T cell responders and incom-
plete T cell responders who had Centers for Disease Control and Pre-
vention (CDC) HIV disease category B or C events. See Methods for
definitions of complete and incomplete CD4 T cell response.
), and duration of HIV infection (adjusted OR, 2.39Pp .003
per 10-year increase; 95% CI, 1.19–4.81; ) indepen-Pp .015
dently predicted a CD4 T cell count !500 cells/mL 5 years after
ART initiation (table 3).
Distinct patterns of incomplete CD4 T cell recovery.
Almost one-half (47.6%) of incomplete responders reached a
plateau in the CD4 T cell count (hereafter, “CD4 T cell plateau”)
that was !500 cells/mL, whereas the CD4 T cell count continued
to increase steadily in the remaining patients (figure 3). Changes
in CD4 T cell kinetics early after the initiation of ART were
very similar for those who reached a CD4 T cell plateau and
those who had a steady CD4 T cell count increase but differed
significantly during the fourth and fifth years of ART (9 cells/
mL vs. 30 cells/mL [ ] and 8 vs. 40 cells/mL [Pp .003 Pp
], respectively). Thus, CD4 T cell kinetics early after ART.001
initiation do not allow discrimination between individuals who
reached a CD4 T cell plateau and individuals who had slow,
but steady CD4 T cell count increases. The only significant
difference between both groups was a higher CD4 T cell count
for individuals who reached a CD4 T cell plateau !500 cells/
mL (93 vs. 58 cells/mL; ). The area under the virus loadPp .021
curve was not associated with a CD4 T cell plateau !500 cells/
mL.
Estimation of the maximum CD4 T cell count. On the
assumptions that ART use will continue indefinitely and that
the plasma HIV-1 RNA load will permanently be !1000 copies/
mL, model simulations suggest that the CD4 T cell count will
reach a maximum of 650 cells/mL (466–883 cells/mL) after a
treatment duration of 51 months (25–97 months). According
to the model, 86.7% of individuals will reach a CD4 T cell
count of 350 cells/mL, and 69.7% will reach a CD4 T cell
count of 500 cells/mL.
Clinical relevance of incomplete CD4 T cell responses.
CDC category B or C events occurred in 49 patients (16.7%)
at a CD4 T cell count of 218 cells/mL (89–307 cells/mL; table
4). Eighteen complete responders (9.6%) experienced clinical
CDC category B events, compared with 14 incomplete respond-
ers (13.3%). Similarly, fewer complete responders experienced
CDC category C events (4.8% vs 7.6%). However, CDC cat-
egory B and C events were not significantly more frequent
among incomplete responders than among complete respond-
ers (21.0% vs. 14.4%; hazard ratio [HR], 1.49; 95% CI, 0.85–
2.62; ; figure 4). Of interest, the incidence of CDCPp .163
category B and C events was similar in both groups during the
first 12 months of ART (12.4% vs. 10.1%; HR, 1.27; 95% CI,
0.63–2.58; ), whereas such events occurred more fre-Pp .501
quently among incomplete responders during years 2–5 after
ART initiation (8.6% vs. 4.3%; HR, 2.04; 95% CI, 0.79–5.28).
However, the difference between the 2 periods was not statis-
tically significant ( ).Pp .143
Prediction of incomplete CD4 T cell recovery. Increases in
the CD4 T cell count early after ART initiation were smaller
in incomplete responders, compared with complete responders
(52 vs. 103 cells/mL 3 months after the start of ART; ).P ! .001
On the basis of these significantly different increases, several
models were tested to predict incomplete response. An increase
of 99 cells/mL in the CD4 T cell count during the first 3 months
after therapy was associated with an 80% sensitivity but only
a 52% specificity to discriminate between complete and in-
complete responders (figure 5A). On the basis of results of the
logistic regression analysis, baseline CD4 T cell count and age
were added to the model (baseline CD4 T cell count 6
monthly CD4 T cell increases/age), which increased the spec-
ificity to 72% while maintaining a sensitivity of 80% as pre-
dictors of CD4 T cell response (figure 5B). The model predicted
incomplete response in a different cohort with similar accuracy
[6].
DISCUSSION
Influence of ART on CD4 T cells has been described in different
settings and with regard to pathophysiology [19–24]. In this
study, we addressed 3 major issues. First, we evaluated the
capacity of the immune system to replenish the depleted pool
of CD4 T cells in patients who had well-suppressed virus levels
during long-term ART. We noted that approximately two-thirds
of patients had reached a CD4 T cell count 1500 cells/mL but
that the remaining one-third showed impaired CD4 T cell re-
covery. Approximately one-half of patients with impaired CD4
T cell recovery had reached a CD4 T cell plateau, showing no
evidence of further increases in CD4 T cell count. Secondly,
we observed that a persistently low CD4 T cell count was as-
sociated more frequently with HIV-related CDC category B and
C clinical events, although the difference between complete and
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Figure 5. Receiver operating characteristic (ROC) curve analyses using baseline CD4 T cell count as the only predictor (A) or using a combination
of baseline CD4 T cell count, early CD4 T cell increase, and age as predictors of CD4 T cell responses (B). The curves shows the trade-off between
sensitivity and specificity. An increase in sensitivity will be accompanied by a decrease in specificity. The accuracy of the prediction increases as the
curve approaches the left-hand and top portions of the ROC space. The area under the curve is the percentage of randomly drawn pairs for which
the prediction is true. The positive predictive value (PPV) is the proportion of patients with positive test results who had poor CD4 T cell responses.
The negative predictive value (NPV) is the proportion of patients with negative test results who did not have poor CD4 T cell responses and is a
measure of whether the prognosis of a poor CD4 T cell response can be ruled out.
incomplete responders was not statistically significant. Third,
we developed a model that may be useful to identify individuals
with incomplete CD4 T cell recovery early after initiation of
ART.
Incomplete responders were characterized by older age and
more advanced HIV infection (as revealed by lower baseline
CD4 and CD8 T cell counts), had a higher rate of CDC category
C events, had had HIV infection for a longer duration, and
had higher baseline plasma HIV RNA levels, compared with
complete responders. In a multivariate model, low CD4 T cell
count, increased age, and a longer duration of HIV infection
independently predicted an incomplete CD4 T cell response.
Age has been previously reported to represent an independent
risk factor for protracted CD4 T cell count restoration [25].
The relative decreases in CD4 T cell counts before ART in-
itiation were parallel for incomplete and complete responders.
This finding did not confirm our hypothesis that the kinetics
associated with decreases in the CD4 T cell count before ART
initiation would predict incomplete and complete CD4 T cell
recovery. However, individuals with larger decreases in the CD4
T cell count before ART initiation had larger increases in the
CD4 T cell count during the first 6 months of ART, as reported
elsewhere [26]. In contrast, long-term CD4 T cell changes dur-
ing ART were not associated with the natural course of CD4
T cell depletion in untreated HIV-1–infected persons before
ART initiation.
Incomplete CD4 T cell responses had 2 main patterns:
achievement of a CD4 T cell plateau !500 cells/mL or a slow
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but steady increase in CD4 T cell count. The CD4 T cell kinetics
associated with these patterns were similar early after ART in-
itiation. However, after 3 years of ART, CD4 T cell kinetics
began to differ. Baseline demographic data were comparable
for both patterns, except for CD4 T cell count, which was
slightly higher in patients who reached a CD4 T cell plateau.
Thus, the 2 distinct patterns of CD4 T cell recovery seem to
be difficult to predict.
Opravil et al. [27] reported that individuals who initiated
ART with !350 CD4 T cells/mL experienced significantly more
CDC category B or C events than did patients who initiated
ART with higher CD4 T cell counts. In the present study, 22
(21.0%) of 105 incomplete responders had clinical CDC cat-
egory B or C events; for 15 (68%), the events were opportunistic
infections. However, in our study, the incidence of HIV-related
events among incomplete responders was not statistically sig-
nificantly different from that among complete responders.
Starting ART late, in association with incomplete CD4 T cell
response, may affect long-term prognosis, even in patients with
good virologic control.
Many CDC category B and C events occurred early after
initiation of ART, affecting incomplete and complete respond-
ers in similar proportions. This suggests that some opportun-
istic infections may have remained undetected before ART and
were unmasked by immune restoration [28, 29]. However, ap-
proximately one-half of clinical events occurred after 1 year of
ART, mainly consisting of new or relapsing infections.
Incomplete responders showed smaller CD4 T cell recovery
during the first 3–6 months of ART. On the basis of these
smaller changes, baseline CD4 T cell count, and age, incomplete
CD4 T cell responses could be predicted with relatively high
accuracy. The high negative predictive value suggests that the
model can reliably rule out an incomplete CD4 T cell response
for some patients. However, the validity of the model requires
further confirmation in different HIV cohorts. In addition, the
model does not yet account for patients with virologic failure.
Mathematical simulations for prediction of longitudinal CD4
T cell counts provided interesting estimations. They predicted
a maximum CD4 T cell count of 650 cells/mL 51 months after
ART initiation in this cohort. Furthermore, the model predicted
that 87% of treated persons will eventually achieve a CD4 T
cell count 350 cells/mL, which is likely to provide adequate
protection against opportunistic infections. A total of 70% will
even achieve a nearly normal CD4 T cell count 500 cells/mL.
It has to be considered that these projections only apply to
patients with good virologic responses who commence ART at
similar baseline CD4 T cell counts.
A limitation of the study was the still relatively short follow-
up period of 5 years. Only an extended observation time beyond
7–8 years will show whether predictions of the model were
correct.
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